Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy

被引:56
作者
Santabarbara, Giuseppe [1 ]
Maione, Paolo [1 ]
Rossi, Antonio [1 ]
Gridelli, Cesare [1 ]
机构
[1] SG Moscati Hosp, Div Med Oncol, Contrada Amoretta 8, Avellino, Italy
关键词
Cisplatin; vomiting; nausea; nephrotoxicity; neurotoxicity; ototoxicity; HIGHLY EMETOGENIC CHEMOTHERAPY; INDUCED PERIPHERAL NEUROPATHY; VITAMIN-E SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; SHORT INTERFERING RNA; INDUCED HEARING-LOSS; NERVE GROWTH-FACTOR; CELL LUNG-CANCER; QUALITY-OF-LIFE; DOUBLE-BLIND;
D O I
10.1517/14656566.2016.1122757
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Cisplatin is widely used in the treatment of several tumors such as lung, ovarian and testicular cancer with different degrees of effectiveness, and its use is burdened by some side effects. Areas covered: This review includes the most important cisplatin side effects such as neurotoxicity, nephrotoxicity, ototoxicity, nausea and vomiting. They can affect patient's quality of life and lead to treatment interruptions with effectiveness reduction. Expert opinion: Specific mechanisms of cisplatin-induced DNA damage and production of reactive oxygen species are the main ones responsible of toxicity. Several clinical approaches have been developed to reduce or prevent these effects with very promising results. The greatest potential for clinical practice is for amifostine, vitamin E, silymarin and NK-1 receptor antagonists.
引用
收藏
页码:561 / 570
页数:10
相关论文
共 120 条
[91]   Sound preconditioning therapy inhibits ototoxic hearing loss in mice [J].
Roy, Soumen ;
Ryals, Matthew M. ;
Van den Bruele, Astrid Botty ;
Fitzgerald, Tracy S. ;
Cunningham, Lisa L. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (11) :4945-4949
[92]   Mechanisms of cisplatin-induced ototoxicity and prevention [J].
Rybak, Leonard P. ;
Whitworth, Craig A. ;
Mukherjea, Debashree ;
Rarakumar, Vickram .
HEARING RESEARCH, 2007, 226 (1-2) :157-167
[93]  
SADZUKA Y, 1992, TOXICOL LETT, V62, P293
[94]   UPTAKE AND METABOLISM OF CISPLATIN BY RAT-KIDNEY [J].
SAFIRSTEIN, R ;
MILLER, P ;
GUTTENPLAN, JB .
KIDNEY INTERNATIONAL, 1984, 25 (05) :753-758
[95]  
Saif MW, 2010, ANTICANCER RES, V30, P2927
[96]   Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial [J].
Saito, Mitsue ;
Aogi, Kenjiro ;
Sekine, Ikuo ;
Yoshizawa, Hirohisa ;
Yanagita, Yasuhiro ;
Sakai, Hiroshi ;
Inoue, Kenichi ;
Kitogawa, Chiyoe ;
Ogura, Takashi ;
Mitsuhashi, Shoichi .
LANCET ONCOLOGY, 2009, 10 (02) :115-124
[97]   HYPOMAGNESEMIA AND RENAL MAGNESIUM WASTING IN PATIENTS RECEIVING CISPLATIN [J].
SCHILSKY, RL ;
ANDERSON, T .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (06) :929-931
[98]   EFFECT OF NERVE GROWTH-FACTOR ON PEPTIDE NEURONS IN DORSAL-ROOT GANGLIA AFTER TAXOL OR CISPLATIN TREATMENT AND IN DIABETIC (DB/DB) MICE [J].
SCHMIDT, Y ;
UNGER, JW ;
BARTKE, I ;
REITER, R .
EXPERIMENTAL NEUROLOGY, 1995, 132 (01) :16-23
[99]   Cisplatin-Induced Hair Cell Death Requires STAT1 and Is Attenuated by Epigallocatechin Gallate [J].
Schmitt, Nicole C. ;
Rubel, Edwin W. ;
Nathanson, Neil M. .
JOURNAL OF NEUROSCIENCE, 2009, 29 (12) :3843-3851
[100]   Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial [J].
Schwartzberg, Lee S. ;
Modiano, Manuel R. ;
Rapoport, Bernardo L. ;
Chasen, Martin R. ;
Gridelli, Cesare ;
Urban, Laszlo ;
Poma, Allen ;
Arora, Sujata ;
Navari, Rudolph M. ;
Schnadig, Ian D. .
LANCET ONCOLOGY, 2015, 16 (09) :1071-1078